Edition:
India

Minerva Neurosciences Inc (NERV.OQ)

NERV.OQ on NASDAQ Stock Exchange Global Market

5.55USD
2:13am IST
Change (% chg)

$0.35 (+6.73%)
Prev Close
$5.20
Open
$5.25
Day's High
$5.55
Day's Low
$5.20
Volume
17,579
Avg. Vol
48,982
52-wk High
$11.15
52-wk Low
$4.90

Chart for

About

Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system (CNS) diseases. The Company's product portfolio and indications include MIN-101 for the treatment... (more)

Overall

Beta: --
Market Cap(Mil.): $320.94
Shares Outstanding(Mil.): 42.51
Dividend: --
Yield (%): --

Financials

BRIEF-Minerva Neurosciences Names Remy Luthringer As Executive Chairman

* MINERVA NEUROSCIENCES NAMES REMY LUTHRINGER AS EXECUTIVE CHAIRMAN AND WILLIAM DOYLE AS LEAD INDEPENDENT DIRECTOR

05 Feb 2018

BRIEF-Minerva Neurosciences Names Remy Luthringer As Executive Chairman

* MINERVA NEUROSCIENCES NAMES REMY LUTHRINGER AS EXECUTIVE CHAIRMAN AND WILLIAM DOYLE AS LEAD INDEPENDENT DIRECTOR

05 Feb 2018

BRIEF-Minerva Neurosciences Screens First Patient In Phase 3 Trial Of MIN-101 To Treat Negative Symptoms In Schizophrenia

* MINERVA NEUROSCIENCES SCREENS FIRST PATIENT IN PHASE 3 TRIAL OF MIN-101 TO TREAT NEGATIVE SYMPTOMS IN SCHIZOPHRENIA

19 Dec 2017

BRIEF-Minerva Neurosciences Screens First Patient In Phase 3 Trial Of Schizophrenia Drug

* MINERVA NEUROSCIENCES SCREENS FIRST PATIENT IN PHASE 3 TRIAL OF MIN-101 TO TREAT NEGATIVE SYMPTOMS IN SCHIZOPHRENIA Source text for Eikon: Further company coverage:

19 Dec 2017

BRIEF-Minerva Neurosciences names Richard Russell president

* MINERVA NEUROSCIENCES INC - REMY LUTHRINGER WILL CONTINUE AS CHIEF EXECUTIVE OFFICER OF MINERVA WHILE RESIGNING HIS POSITION AS PRESIDENT Source text for Eikon: Further company coverage:

12 Dec 2017

BRIEF-Minerva Neurosciences reports Q3 loss per share $0.28

* Minerva Neurosciences Inc reports third quarter 2017 financial results and business updates

06 Nov 2017

BRIEF-Minerva Neurosciences announces enrollment of first patient in phase 2b trial of seltorexant

* Minerva Neurosciences announces enrollment of first patient in phase 2b trial of seltorexant (min-202) as adjunctive therapy in patients with major depressive disorder

05 Sep 2017

BRIEF-Minerva Neurosciences announces enrollment of first patient in phase 2B trial of Seltorexant

* Minerva Neurosciences announces enrollment of first patient in phase 2B trial of Seltorexant (MIN-202) as adjunctive therapy in patients with major depressive disorder

05 Sep 2017

BRIEF-Minerva Neurosciences announces European Commission approval of amendment of MIN-202 agreement with Janssen

* Minerva Neurosciences announces European Commission approval of amendment of MIN-202 agreement with Janssen

25 Aug 2017

Competitors

Earnings vs. Estimates